Prohibiting Tianeptine and Other Dangerous Products Act of 2026
- Bill Number
- S. 3797
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 2
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2026-02-05: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S512)
- Last Updated
- 2026-02-26T18:18:20Z
AI-Generated Summary
Purpose
The legislation aims to strengthen regulations on dietary supplements by prohibiting the sale or distribution of products that do not qualify as legitimate dietary supplements under federal law and those produced with involvement from individuals or entities barred from the industry. It targets unsafe or misrepresented products, such as those containing unapproved substances like tianeptine (an antidepressant not approved as a dietary supplement in the U.S.), to protect public health.
Key Provisions
- Prohibited Acts for Dietary Supplements:
- Bans the introduction or delivery into interstate commerce (trade across state lines) of any product marketed as a dietary supplement if it fails to meet the legal definition of a dietary supplement under Section 201(ff) of the Federal Food, Drug, and Cosmetic Act (FD&C Act). This definition typically includes vitamins, minerals, herbs, or other substances intended to supplement the diet, excluding drugs, medical devices, or food additives.
- Prohibits the introduction or delivery into interstate commerce of a dietary supplement that was prepared, packed, or held (stored) with the help of or under the direction of a person debarred under Section 306 of the FD&C Act. Debarment is a penalty that bars individuals or companies from participating in drug or supplement production due to past violations like fraud or unsafe practices.
- Import Restrictions:
- Updates import rules under Section 801(a) of the FD&C Act to exclude from entry any imported products violating these new prohibitions, alongside existing rules.
- Seizure Powers:
- Expands FDA seizure authority under Section 304 of the FD&C Act to include products that violate the new rules, allowing the government to confiscate adulterated or misbranded supplements at the border or within the U.S.
Significant Changes to Existing Law
- Adds two new prohibited acts (Sections 301(jjj) and 301(kkk)) to the FD&C Act, which previously lacked specific bans on mislabeled dietary supplements or those linked to debarred parties.
- Integrates these prohibitions into existing enforcement tools, such as import exclusions and seizures, which previously only covered certain other violations (e.g., under Section 301(ll) for unapproved drugs).
- Enhances overall accountability in the dietary supplement industry, which has lighter regulation compared to drugs, by closing loopholes that allowed non-compliant or tainted products to enter the market.
Potential Impacts
- On Government Agencies: The Food and Drug Administration (FDA) gains broader tools to enforce supplement regulations, potentially increasing inspections, seizures, and import refusals, which could strain resources but improve compliance.
- On Citizens: Consumers may benefit from reduced access to unsafe or fraudulent supplements, lowering risks of health issues from unapproved ingredients (e.g., tianeptine, linked to addiction and overdose). However, it could limit availability of some niche products.
- On International Relations: Strengthens U.S. border controls on imports, possibly affecting trade with countries exporting supplements, and signals stricter standards that could influence global manufacturing practices.
Main Stakeholders Affected
- Dietary Supplement Manufacturers and Sellers: Face stricter compliance requirements, with risks of product seizures or bans for non-qualifying items or debarred involvement.
- Importers and Distributors: Must verify product legitimacy and origins, impacting supply chains for international goods.
- Debarred Individuals or Entities: Further restricted from industry participation, limiting their influence.
- Consumers and Public Health Advocates: Gain protections against dangerous products but may see higher prices or fewer options if enforcement reduces market supply.
- FDA and Health Regulators: Empowered with new authorities to monitor and act against violations.
Notable Legal, Constitutional, or Political Implications
- Legal: Bolsters the FD&C Act's framework for supplements (regulated since the 1994 Dietary Supplement Health and Education Act), emphasizing pre-market compliance without requiring full drug-like approval processes. It could lead to more lawsuits or enforcement actions against violators.
- Constitutional: Aligns with Congress's authority under the Commerce Clause to regulate interstate trade and protect public health; no apparent conflicts with free speech or due process, as it targets conduct (marketing and distribution) rather than speech.
- Political: Reflects bipartisan concern over supplement safety amid rising reports of harms from substances like tianeptine; may spur further reforms in the loosely regulated $50 billion supplement industry, potentially facing opposition from industry groups favoring lighter oversight.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Sen. Durbin, Richard J. [D-IL]
Cosponsors (1)
Sen. Blumenthal, Richard [D-CT]
Recent Actions
- 2026-02-05: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S512)
- 2026-02-05: Introduced in Senate
Bill Versions
- Prohibiting Tianeptine and Other Dangerous Products Act of 2026 — issued 2026-02-05 — PDF (2 pages)